BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20950443)

  • 21. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.
    Chai H; Luo AZ; Weerasinghe P; Brown RE
    Int J Clin Exp Pathol; 2010 Apr; 3(4):408-15. PubMed ID: 20490331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
    Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
    Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
    Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Halling T; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
    Am J Hematol; 2012 Mar; 87(3):277-83. PubMed ID: 22190165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.
    Zhao W; Gu YH; Song R; Qu BQ; Xu Q
    Leukemia; 2008 Jun; 22(6):1226-33. PubMed ID: 18337760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.
    Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Liver Int; 2012 Apr; 32(4):574-81. PubMed ID: 22176637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
    Panka DJ; Wang W; Atkins MB; Mier JW
    Cancer Res; 2006 Feb; 66(3):1611-9. PubMed ID: 16452220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
    Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
    Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH
    J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
    Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
    Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP
    Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
    Baradari V; Höpfner M; Huether A; Schuppan D; Scherübl H
    World J Gastroenterol; 2007 Sep; 13(33):4458-66. PubMed ID: 17724801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism.
    Chiou JF; Tai CJ; Wang YH; Liu TZ; Jen YM; Shiau CY
    Cancer Biol Ther; 2009 Oct; 8(20):1904-13. PubMed ID: 19770576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.